patientMpower announces new agreement with ERASMUS MC European Expert Centre for Interstitial Lung Disease

    European Centre for Excellence selects remote monitoring specialist patientMpower as technology partner for digital care of the complex lung disease ILD

    Digital healthcare company patientMpower have announced a new agreement with ERASMUS MC, a European Expert Centre for Interstitial Lung Disease (ILD) and Sarcoidosis.

    The agreement will see patientMpower providing technology to enable a new digitally-enabled care pathway for patients with ILD being managed by the Rotterdam-based Centre of Excellence, along with ten further Dutch clinical sites. The selection of patientMpower technology by the expert centre, home to leading researchers on e-health for ILD patient care, is significant validation of patientMpower’s platform and the Company’s expertise in this field.

    The home monitoring programme is expected to generate robust evidence on the health and economic outcomes of a digital approach to ILD care. The intention is that evidence generated by this programme will form the basis of a reimbursement application for the digital health technology for pulmonary diseases in the Netherlands. However, given the centre’s specialist expertise, it is expected the work will have far wider implications for the use of digital technology for ILD care. Seen by many as the thought-leading centre on home monitoring for ILD globally, the approach taken by ERASMUS MC serves as a benchmark for ILD care pathway redesign across Europe and beyond.

    The announcement was made at the European Pulmonary Fibrosis Patient Summit, a biennial patient-led event which supports collaboration between patient advocates, healthcare professionals, researchers, industry, and policymakers to promote ILD education and patient empowerment.

    Speaking at the event Prof. Dr. Marlies Wijsenbeek, Chair of the Erasmus MC Multidisciplinary ILD Centre said; “Home monitoring can transform the way we manage ILD; improving access to specialist care, enabling a collaborative and patient-centred approach, identifying disease worsening earlier and reducing the burden on healthcare systems. Ultimately, combined with innovations in telemedicine and automated algorithms it has the potential to revolutionise health-care delivery. My colleagues and I at ERASMUS MC have spent many years researching home monitoring of ILD. This very much informed the list of functionality we required from our technology partner, leading to this agreement with patientMpower. The team is excited to now begin using patientMpower technology in our daily care.”

    Eamonn Costello, CEO of patientMpower said “We have invested heavily in generating a strong evidence base for our platform in ILD over many years, and we have always held the research of Prof. Dr. Wijsenbeek and the ERASMUS MC team in the highest regard. I see this as a joining of forces, enabling us to scale a digital approach to care of patients with ILD across healthcare systems worldwide. There are also many more patients with other pulmonary conditions, from severe COPD and asthma through to rare respiratory diseases, could also benefit from a similar digital approach.”

    Liam Galvin, CEO of the European Pulmonary Fibrosis Federation (EU-PFF) said; “The need for a greater focus on patient centered care is one of the key themes of our 2024 European Pulmonary Fibrosis Patient Summit is so it’s fitting that we should be celebrating news of the agreement between patientMpower and ERASMUS MC here. Technology not only enables clinicians to provide high-quality individualised care for their patients, it can empower patients to self-manage their condition too. It’s a great example of how the collaboration we promote through EU-PFF can improve the lives of people living with pulmonary fibrosis”.

    This will be the first deployment of patientMpower technology in the Dutch market, and further European expansion is planned. The Company currently works with clinical centres and research organisations in the UK, Germany, Ireland, Belgium, US and Canada.


    About patientMpower

    patientMpower is a specialist provider of digital health solutions. Established in 2015, our experience in transformation of clinical care spans across the EU, UK and North America. Our mission is to empower patient-centred specialist healthcare & data insights through digital innovation.


    About ILD research at ERASMUS MC

    Erasmus MC, situated in Rotterdam, the Netherlands, is a university medical center renowned for its excellence in both clinical practice and scientific research. The ILD research team of Erasmus Medical Centre is recognized as a leading advocate for eHealth in ILDs worldwide. Their mission is to enhance patient-centered care by empowering individuals through self-management tools, with a particular focus on enhancing the quality of life for patients with pulmonary fibrosis and their caregivers.